Efficacious signals from adjuvant ICI in other solid tumor subtypes, combined with proven efficacy of PD-L1 inhibition in the metastatic NSCLC setting, prompted investigation as to whether adjuvant use of ICI could provide further benefit to adjuvant chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.